Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q14767
UPID:
LTBP2_HUMAN
Alternative names:
-
Alternative UPACC:
Q14767; Q99907; Q9NS51
Background:
Latent-transforming growth factor beta-binding protein 2 plays a crucial role in the structural organization and assembly of elastic fibers, essential components of the connective tissue. This protein's involvement in the extracellular matrix's architecture underscores its importance in tissue development and integrity.
Therapeutic significance:
Linked to diseases such as primary congenital glaucoma, microspherophakia with or without secondary glaucoma, and Weill-Marchesani syndrome 3, understanding the role of Latent-transforming growth factor beta-binding protein 2 could open doors to potential therapeutic strategies. These conditions, characterized by eye abnormalities and connective tissue disorders, highlight the protein's clinical relevance.